Novel lymphokine for suppressing platelet activation
US5071959A · kind A · utility
1Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 1, 1988 |
| Grant date | Dec 10, 1991 |
| Priority date | — |
| Expiry date | Mar 1, 2008 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New lymphokine and its isolation and purification process. Said lymphokine is comprised of a factor obtained from T cells stimulated by concanavaline A or by an antigen capable of inhibiting the IgE-dependent platelet citotoxicity with respect to young larvae of S. Mansoni, of strongly reducing the chemiluminescence of blood platelets in a reaction IgE-anti-IgE, which is a correlate of the anti-parasite cytotoxicity, and of inhibiting the platelet activation in non-IgE dependent intolerences. Application as suppressor agent for suppressing platelet activation and as immunomodulator medicament of allergies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.